The antiviral remdesvir has been approved by the US Food and Drug Administration for the treatment of patients hospitalized with Covid-19, Gilead Sciences announced Thursday.
The drug, sold under the brand name Veklury, has been used under emergency use authorization (EUA) in the US. It is the first drug to be approved in the US for treating Covid-19.
“In the United States, Veklury is indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of Covid-19 requiring hospitalization,” the company said in a statement. “Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care.”
Some context: Earlier this month, a World Health Organization-sponsored global study found remdesivir did not help patients survive or even recover faster, but a US study found the infused drug shortened recovery time for some patients by about a third.